A company like Merck needn't be gunshy about forking over big bucks to engage NWBO in a partnership. I suspect the anticipated high cost of stacking treatment modalities such as Keytruda+DCVAX would have come up in discussions BTW parties, and potential pricing models for reimbursement. Let's assume that Merck negotiates earning a percentage of DCVAX sales when combined with Keytruda. Merck has an opportunity to double dip. So part of the negotiations, I would imagine would have focused on getting the closed loop Flaskworks units approved, and ready to scale. It could explain why we haven't heard an announcement of a finalized partnership, because things are still dynamic at this juncture, yet not for much longer.
Market Data 
Markets 
